Search Results
You are looking at 1 - 3 of 3 items for
- Author: Yi Pan x
- Refine by access: All content x
Search for other papers by Shuai Dong in
Google Scholar
PubMed
Search for other papers by Jun Pan in
Google Scholar
PubMed
Search for other papers by Yi-Bin Shen in
Google Scholar
PubMed
Search for other papers by Li-Xian Zhu in
Google Scholar
PubMed
Search for other papers by Liang Chen in
Google Scholar
PubMed
Search for other papers by Feng Zhu in
Google Scholar
PubMed
Search for other papers by Hui Li in
Google Scholar
PubMed
Search for other papers by Hai-Xiang Shen in
Google Scholar
PubMed
Search for other papers by Qing Xia in
Google Scholar
PubMed
Search for other papers by Yi-Jun Wu in
Google Scholar
PubMed
Search for other papers by Xiao-Jun Xie in
Google Scholar
PubMed
Thyroid cancer is one of the most common endocrine malignancies. It is necessary to discover more effective molecular targets for the treatment of thyroid cancer. The results of immunohistochemical staining, qPCR and Western blot indicated that the expression of SYT7 in thyroid cancer tissues and cells was higher than that in paracarcinoma tissues and normal thyroid cells. Through cell function testing experiments, it was found that SYT7 knockdown inhibited the proliferation and migration of thyroid cancer cells and promoted cell apoptosis, while SYT7 overexpression had the opposite effect. Similarly, SYT7 downregulation also suppressed tumor growth in vivo. HMGB3 was confirmed to be the downstream gene of SYT7 by GeneChip and Ingenuity Pathway Analysis. Besides, through UbiBrowser database predictions and Co-IP assays, we found that SYT7 interacted with BRCA1 to inhibit HMGB3 ubiquitination and thus upregulated the protein level of HMGB3. Similar to SYT7, HMGB3 was significantly upregulated in thyroid cancer. HMGB3 knockdown inhibited the proliferation and migration of thyroid cancer cells and promoted cell apoptosis. Furthermore, HMGB3 knockdown restored the promotion of cell proliferation and migration caused by SYT7 overexpression. SYT7 and HMGB3 were upregulated in thyroid cancer, and SYT7 regulated the expression of HMGB3 through BRCA1-mediated ubiquitination of HMGB3 to promote thyroid cancer progression.
Search for other papers by Xianhui Ruan in
Google Scholar
PubMed
Search for other papers by Jiaoyu Yi in
Google Scholar
PubMed
Search for other papers by Linfei Hu in
Google Scholar
PubMed
Search for other papers by Jingtai Zhi in
Google Scholar
PubMed
Search for other papers by Yu Zeng in
Google Scholar
PubMed
Search for other papers by Xiukun Hou in
Google Scholar
PubMed
Search for other papers by Jianfeng Huang in
Google Scholar
PubMed
Search for other papers by Pengfei Gu in
Google Scholar
PubMed
Search for other papers by Weijing Hao in
Google Scholar
PubMed
Department of Thyroid and Breast Surgery, Tianjin Union Medical Center, Tianjin, People’s Republic of China
Search for other papers by Ming Gao in
Google Scholar
PubMed
Search for other papers by Yi Pan in
Google Scholar
PubMed
Search for other papers by Songfeng Wei in
Google Scholar
PubMed
Search for other papers by Xiangqian Zheng in
Google Scholar
PubMed
Increasing body of recent studies determining the expression of tumor-specific major histocompatibility complex (MHC) class II protein supports its potential role in several malignancies, but little is known in human medullary thyroid cancer (MTC). Here, we report the expression of MHC-II and its clinicopathologic and prognostic relevance in MTC patients. Immunohistochemistry staining revealed a significant reduction in tumor cell-specific MHC-II expression in a higher AJCC stage and its poor prognostic correlation with human MTC development. Further statistical analysis identified the low MHC-II expression as a significant and independent risk factor for MTC recurrence and patient survival. Moreover, in vitro studies showed that the MHC-II expression was remarkably increased by RET inhibitors, which were prescribed to treat advanced MTC. Similarly, inhibitors blocking the MAPK/ERK and AKT/mTOR pathways also augmented MHC-II expression, suggesting their implications in RET-MHC-II signaling axis. Importantly, in vitro assays manifested enhanced peripheral blood leukocytes-mediated cytotoxicity in MTC cells treated with RET inhibitors, which were partially alleviated by HLA knock-down. Together, our study demonstrates that low MHC-II expression levels may serve as a prognostic biomarker for aggressive diseases in MTC patients and indicates that RET activation may promote MTC immune escape through downregulating MHC-II expression.
Search for other papers by Xi Wei in
Google Scholar
PubMed
Department of Radiotherapy and Oncology, the Second Affiliated Hospital of Soochow University, Suzhou, China
Search for other papers by Shang Cai in
Google Scholar
PubMed
Search for other papers by Rebecca J Boohaker in
Google Scholar
PubMed
Search for other papers by Joshua Fried in
Google Scholar
PubMed
Search for other papers by Ying Li in
Google Scholar
PubMed
Search for other papers by Linfei Hu in
Google Scholar
PubMed
Search for other papers by Yi Pan in
Google Scholar
PubMed
Search for other papers by Ruifen Cheng in
Google Scholar
PubMed
Search for other papers by Sheng Zhang in
Google Scholar
PubMed
Search for other papers by Ye Tian in
Google Scholar
PubMed
Search for other papers by Ming Gao in
Google Scholar
PubMed
Department of Molecular Radiation Oncology, Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Search for other papers by Bo Xu in
Google Scholar
PubMed
Anaplastic thyroid cancer (ATC) is an aggressive cancer with poor clinical prognosis. However, mechanisms driving ATC aggressiveness is not well known. Components of the DNA damage response (DDR) are frequently found mutated or aberrantly expressed in ATC. The goal of this study is to establish the functional link between histone acetyltransferase lysine (K) acetyltransferase 5 (KAT5, a critical DDR protein) and ATC invasiveness using clinical, in vitro and in vivo models. We analyzed the expression of KAT5 by immunohistochemistry and assessed its relationship with metastasis and overall survival in 82 ATC patients. Using cellular models, we established functional connection of KAT5 expression and C-MYC stabilization. We then studied the impact of genetically modified KAT5 expression on ATC metastasis in nude mice. In clinical samples, there is a strong correlation of KAT5 expression with ATC metastasis (P = 0.0009) and overall survival (P = 0.0017). At the cellular level, upregulation of KAT5 significantly promotes thyroid cancer cell proliferation and invasion. We also find that KAT5 enhances the C-MYC protein level by inhibiting ubiquitin-mediated degradation. Further evidence reveals that KAT5 acetylates and stabilizes C-MYC. Finally, we prove that altered KAT5 expression influences ATC lung metastases in vivo. KAT5 promotes ATC invasion and metastases through stabilization of C-MYC, demonstrating it as a new biomarker and therapeutic target for ATC.
